Evolucumab did not show increased risks for neurocognitive events, diabetes, heart failure, or stroke, but did show an increased risk of all-cause mortality.

“Ali ruab seems to decrease the risk so we'll talk about this and then there's some other interesting things that we can talk about as well so the study is titled serious Adverse Events and deaths and pcsk9 trials reported on clinical trials.gov assist systematic review this is a systematic review they say in clinical outcome studies pcsk9 Inhibitors in general did not affect the risk of all cause serious Adverse Events compared to Placebo but Ali roab decreased the risk the risk of death was not significantly different between the pcsk9 inhibitor versus placebo groups in the lipid lowering studies and clinical outcome studies however for eval lucab the risk mortality was 1.18 times in lipid lowering trials and 1.12 times in clinical outcome Tri trial for a year”